190 research outputs found
Hopf and Lie algebras in semi-additive varieties
No full textCITATION: Porst, H. E. 2017. Hopf and Lie algebras in semi-additive Varieties. Logical Methods in Computer Science, 13(2):1-13, doi:10.23638/LMCS-13(2:3)2017.The original publication is available at https://lmcs.episciences.org/3315We study Hopf monoids in entropic semi-additive varieties with an emphasis on adjunctions related to the enveloping monoid functor and the primitive element functor. These investigations are based on the concept of the abelian core of a semi-additive variety variety and its monoidal structure in case the variety is entropic.https://lmcs.episciences.org/3315Publisher's versio
Kiri C. H. Canstein'ile
No full textPorst, Johann, 1668-1728, saksa teoloog, pastor BerliinisCanstein, Carl Hildebrandt, 1667-1719, teoloogPalub arvamust kirikliku patukahetsuse deklaratsioonil
Vardenafil improves satisfaction rates, depressive symptomatology, and self- confidence in a broad population of men with erectile dysfunction
No full textEfficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial
No full textBackground: Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH-LUTS). Objective: To assess efficacy, including onset, and safety of tadalafil on BPH-LUTS and the subject's and clinician's perception of changes in urinary symptoms. Design, setting, and participants: This randomized, double-blind, placebo-controlled, 12-week trial enrolled men >= 45 yr of age with BPH-LUTS for >6 mo, International Prostate Symptom Score (IPSS) >= 13, and maximum urine flow rate (Q(max)) >= 4 to <= 15 ml/s. Intervention: Tadalafil 5 mg (n = 161) or placebo (n = 164), once daily. Measurements: Analysis of covariance (ANCOVA) modeling evaluated change from baseline in continuous efficacy variables. Categoric efficacy variables were analyzed with the Cochran-Mantel-Haenszel test, and between-group differences in treatment-emergent adverse events (TEAEs) were assessed using the Fisher exact test. Results and limitation: Tadalafil significantly improved IPSS results, from baseline to endpoint, compared to placebo (-5.6 vs -3.6; p = 0.004). Reduction in IPSS results was apparent after 1 wk and significant after 4 wk (tadalafil -5.3 vs placebo -3.5; p = 0.003). The BPH Impact Index (BII) was not assessed at week 1; however, BII improvement was apparent at 4 wk (tadalafil -1.8 vs placebo -1.2; p = 0.029) and continued at 12 wk (tadalafil -1.8 vs placebo -1.3; p = 0.057). Tadalafil significantly improved the International Index of Erectile Function-Erectile Function score in sexually active men with erectile dysfunction (ED; 6.7 vs 2.0; p < 0.001) at 12 wk (not assessed at week 1). Few subjects reported one TEAE or more (p = 0.44). For tadalafil, the most common TEAEs were headache (3.7%) and back pain (3.1%). Tadalafil did not significantly improve Q(max) or reduce postvoid residual volume. Conclusions: Tadalafil 5 mg once daily for 12 wk resulted in a clinically meaningful reduction in total IPSS results as early as 1 wk and achieved statistical significance at 4 wk in men with BPH-LUTS. The adverse event profile was consistent with that previously reported in men with ED. Trial registration: This clinical trial is registered on the clinicaltrials.gov website (http://www.clinicaltrials.gov). The registration number is NCT00827242. (C) 2011 Published by Elsevier B. V. on behalf of European Association of Urology
The Lost Penis Syndrome: A New Clinical Entity in Sexual Medicine
No full textIntroduction: The “lost penis syndrome” (LPS) is a term often used in non-clinical settings to describe the subjective perception of the loss of cutaneous and proprioceptive feelings of the male organ during vaginal penetration. Although deserving clinical attention, this syndrome did not receive any consideration in the medical literature. Notwithstanding, it represents a relatively unexceptional condition among patients in sexual medicine clinics, and it is often reported together with other sexual dysfunctions, especially delayed ejaculation, anejaculation, male anorgasmia and inability to maintain a full erection. Objectives: To draft a new conceptual characterization of the LPS, defined as a lack of penile somesthetic sensations during sexual penetration due to various causes and leading to several sexual consequences in both partners. Methods: Based on an extensive literature review and physiological assumptions, the mechanisms contributing to friction during penovaginal intercourse, and their correlation to LPS, have been explored, as well as other nonanatomical factors possibly contributing to the loss of penile sensations. Results: Efficient penile erection and sensitivity, optimal vaginal lubrication and trophism contribute to penovaginal friction. Whenever one of these processes does not occur, loss of penile sensation defined as LPS can occur. Sociocultural, psychopathological and age-related (ie, couplepause) factors are also implicated in the etiology. Four types of LPS emerged from the literature review: anatomical and/or functional, behavioral, psychopathological and iatrogenic. According to the subtype, a wide variety of treatments can be employed, including PDE5i, testosterone replacement therapy and vaginal cosmetic surgery, as well as targeted therapy for concomitant sexual comorbidity. Conclusion: We held up the mirror on LPS as a clinically existing multifactorial entity and provided medical features and hypotheses contributing to or causing the occurrence of LPS. In the light of a sociocultural and scientific perspective, we proposed a description and categorization of this syndrome hypothesizing its usefulness in daily clinical practice. Colonnello E, Limoncin E, Ciocca G, et al. The Lost Penis Syndrome: A New Clinical Entity in Sexual Medicine. Sex Med Rev 2022;10:113–129
Preliminary Validation of a German Version of the Sexual Complaints Screener for Women in a Female Population Sample
No full textBackground: To date, neither the original English nor any of the translated versions of the Sexual Complaints Screener for Women (SCS-W) have been tested for their psychometric properties. Aim: To evaluate the validity and utility of the German version of the SCS-W by assessing content, convergent, and discriminant validity. Methods: A population sample of 309 women (mean age = 26.9 years) completed the online survey and had matching data available on the SCS-W and the Female Sexual Function Index (FSFI). Spearman bivariate correlations between the SCS-W and FSFI domain scores and exploratory factor analysis with principal component analysis were conducted. Outcomes: Convergent validity was excellent for the domain of orgasm, good for satisfaction, dyspareunia, and the total questionnaire score, and acceptable for desire, lubrication, arousal, and vaginismus. Discriminant validity was present for all domains apart from arousal, lubrication, and vaginismus. Varimax rotation suggested an 8-factor model was the most robust. Clinical Implications: This brief screener seems suitable to provide a brief overview of female patients' sexual problems in a clinical setting. Strengths and Limitations: This is the 1st study to assess the psychometric properties of the German version of the SCS-W. However, available information on the psychometric properties of the German SCS-W was limited because the validity of the screener could not be counterchecked against a clinical diagnosis of female sexual dysfunction. Conclusion: Our results provide preliminary evidence of good validity of the German version of the SCS-W. Overall, the SCS-W can offer support for clinicians who are less familiar with sexual medicine and who might not routinely discuss sexual issues with their patients.Burri A, Porst H. Preliminary Validation of a German Version of the Sexual Complaints Screener for Women in a Female Population Sample. Sex Med 2018;6:123–130. Key Words: Female Sexual Dysfunction, Assessment, Sexual Complaints Screener for Women (SCS-W), Validation, Psychometric Properties, Screene
Birkhoff's Covariety Theorem without limitations
No full textsummary:J. Rutten proved, for accessible endofunctors of {\bf Set}, the dual Birk\-hoff's Variety Theorem: a collection of -coalgebras is presentable by coequations ( subobjects of cofree coalgebras) iff it is closed under quotients, subcoalgebras, and coproducts. This result is now proved to hold for all endofunctors of {\bf Set} provided that coequations are generalized to mean subchains of the cofree-coalgebra chain. For the concept of coequation introduced by H. Porst and the author, which is a subobject of a member of the cofree-coalgebra chain, the analogous result is false, in general. This answers negatively the open problem of A. Kurz and J. Rosick'y whether every covariety can be presented by equations w.r.t. co-operations. In contrast, in the category of classes Birkhoff's Covariety Theorem is proved to hold for all endofunctors (using Rutten's original concept of coequations)
- …
